作者: Jennifer Y Chen , Anthony C Ogwu , Petr Svab , Shahin Lockman , Howard J Moffat
DOI: 10.1097/QAI.0B013E3181C080BF
关键词:
摘要: BACKGROUND Botswana has the most comprehensive public program in Africa for providing antiretroviral therapy to treat HIV and prevent mother-to-child transmission (PMTCT). guidelines prioritize CD4(+) cell count testing during pregnancy initiation of highly active treatment (HAART) women who qualify treatment. We analyzed rates testing, CD4 HAART pregnancy. METHODS From October 2007 through June 2008, we reviewed obstetric laboratory records at Princess Marina Hospital Gaborone, Botswana. RESULTS recorded information from 3056 women. Of 2675 eligible PMTCT program, 2623 (98%) had a documented status, whom 793 (30%) were infected. Among naive conception, 397 (59%) counts, 62 (16%) <200 cells per cubic millimeter. this subset, 23 (37%) initiated pregnancy, 26 (42%) received zidovudine prophylaxis, 13 (21%) no therapy. CONCLUSIONS observed low Antenatal clinics should referral maximize benefits maternal PMTCT.